<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: PROX1 is a specific target of the Î²-catenin/TCF pathway in the intestinal epithelium </plain></SENT>
<SENT sid="1" pm="."><plain>It acts as a regulator of progression from a benign to a highly dysplastic phenotype in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumours</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, the clinical significance of PROX1 expression is not known </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We studied the prognostic value of immunohistochemical expression of PROX1 in a series of 517 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The majority of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> samples expressed PROX1 (91%, 471 out of 517) </plain></SENT>
<SENT sid="5" pm="."><plain>High PROX1 expression was associated with a poor grade of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> differentiation (P&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>In the subgroup of patients with <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, high PROX1 expression was associated with unfavourable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific survival (CCSS) as compared with low PROX1 expression (CCSS 47% vs 62%; P=0.045; RR 1.47) </plain></SENT>
<SENT sid="7" pm="."><plain>The association between high PROX1 and poor outcome was further strengthened in female <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients (CCSS 38% vs 63%; P=0.007; RR 2.02) </plain></SENT>
<SENT sid="8" pm="."><plain>Nonetheless, in multivariate survival analysis PROX1 expression was not retained as an independent prognostic factor </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: High PROX1 expression is associated with a poor grade of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> differentiation, and, in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients, also with less favourable patient outcome </plain></SENT>
<SENT sid="10" pm="."><plain>Our results strengthen the previous preclinical observations that PROX1 has a role in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumour progression</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>